{"id":"W2187343014","doi":"10.1016/s2352-3026(15)00197-0","title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"AbbVie Biotherapeutics; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Thalidomide; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002358057,0.001809361,0.003153682,0.0004925996,0.0003104039,0.001401018,0.001139459,0.001628492,0.003617204],"category_scores_gemma":[0.001527068,0.0007600004,0.002116345,0.0005208974,0.001201005,0.001834707,0.0006528625,0.003639708,0.001039931],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001317704,"about_ca_system_score_gemma":0.001093997,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001162795,"about_ca_topic_score_gemma":0.002137512,"domain_scores_codex":[0.9991091,0.0004459813,0.00004770909,0.0001346804,0.00007798094,0.0001844298],"domain_scores_gemma":[0.999054,0.0002564512,0.0002032317,0.00009358893,0.00005361674,0.0003391757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9275394,0.01264234,0.002298682,0.0004185851,0.001748505,0.00007089993,0.0001531431,0.001382995,0.005314742,0.0001121353,0.001470161,0.04684843],"study_design_scores_gemma":[0.9102726,0.08041622,0.006191425,0.0000276466,0.0005223996,0.00006639257,0.0000431806,0.0004960695,0.0006858014,0.0001706203,0.001081399,0.00002621234],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935279,0.003057279,0.0003219079,0.0006671734,0.0001633123,0.0005525969,0.0006335152,0.00007434271,0.001001845],"genre_scores_gemma":[0.9900745,0.001955298,0.001327954,0.001512922,0.0002615376,0.0007728054,0.001659249,0.00004597832,0.00238965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003617204,"threshold_uncertainty_score":0.01247078,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1136967265332321,"score_gpt":0.3721539367962131,"score_spread":0.258457210262981,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}